Effects of Zimen powder on persistent HR-HPV infection of the cervix and cervical regulatory T cells

注册号:

Registration number:

ITMCTR2100004264

最近更新日期:

Date of Last Refreshed on:

2021-01-14

注册时间:

Date of Registration:

2021-01-14

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

子门散对宫颈 HR-HPV 持续性感染及宫颈调节性 T 细胞的影响

Public title:

Effects of Zimen powder on persistent HR-HPV infection of the cervix and cervical regulatory T cells

注册题目简写:

English Acronym:

研究课题的正式科学名称:

子门散对宫颈 HR-HPV 持续性感染及宫颈调节性 T 细胞的影响

Scientific title:

Effects of Zimen powder on persistent HR-HPV infection of the cervix and cervical regulatory T cells

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100042159 ; ChiMCTR2100004264

申请注册联系人:

辛雪艳

研究负责人:

辛雪艳

Applicant:

Xueyan Xin

Study leader:

Xueyan Xin

申请注册联系人电话:

Applicant telephone:

+86 13911345226

研究负责人电话:

Study leader's telephone:

+86 13911345226

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

xxyfzx@163.com

研究负责人电子邮件:

Study leader's E-mail:

xxyfzx@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市海淀区西苑操场一号中国中医科学院西苑医院妇科

研究负责人通讯地址:

北京市海淀区西苑操场一号中国中医科学院西苑医院妇科

Applicant address:

Department of Gynecology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, 1 Xiyuan Playground, Haidian District, Beijing

Study leader's address:

Department of Gynecology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, 1 Xiyuan Playground, Haidian District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国中医科学院西苑医院

Applicant's institution:

Xiyuan Hospital China Academy of Chinese Medical Sciences

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

中国中医科学院西苑医院医学伦理委员会2019XLA069-2

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

中国中医科学院西苑医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Xiyuan Hospital, China Academy of Chinese Medical Sciences

伦理委员会批准日期:

Date of approved by ethic committee:

2020/1/9 0:00:00

伦理委员会联系人:

訾明杰

Contact Name of the ethic committee:

Mingjie Zi

伦理委员会联系地址:

北京市海淀区西苑操场一号

Contact Address of the ethic committee:

1 Xiyuan Playground, Haidian District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 13911345226

伦理委员会联系人邮箱:

Contact email of the ethic committee:

xxyfzx@163.com

研究实施负责(组长)单位:

中国中医科学院西苑医院

Primary sponsor:

Xiyuan Hospital China Academy of Chinese Medical Sciences

研究实施负责(组长)单位地址:

北京市海淀区西苑操场一号

Primary sponsor's address:

1 Xiyuan Playground, Haidian District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院

具体地址:

海淀区西苑操场一号

Institution
hospital:

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences

Address:

1 Xiyuan Playground, Haidian District

经费或物资来源:

中国中医科学院西苑医院苗圃课题

Source(s) of funding:

Miaopu subject of Xiyuan Hospital of China Academy of Chinese Medical Scinences

研究疾病:

宫颈持续性HR-HPV感染

研究疾病代码:

Target disease:

Persistent HR-HPV infection of the cervix

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

1.探索中药对宫颈 HR-HPV 持续性感染的治疗作用,为治疗 HR-HPV 持续性感染提供新方法。 2.探索中药对宫颈 HR-HPV 持续性感染治疗机制。

Objectives of Study:

1.To explore the therapeutic effect of Traditional Chinese medicine on persistent HR-HPV infection of the cervix, and to provide a new method for treating HR-HPV persistent infection. 2.to explore the mechanism of traditional Chinese medicine for the treatment of cervical HR-HPV persistent infection

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

①符合宫颈 HR-HPV 持续性感染的诊断标准。 ②证属湿热下注者。 ③患者年龄在 25-49 岁之间。 ④患者知情同意,并自愿签署知情同意书。 ⑤未绝经、非哺乳期女性。 ⑥近 1 年无妊娠计划。

Inclusion criteria

1. Meet the diagnostic criteria for persistent HR-HPV infection of the cervix; 2. Conform to Chinese medicine syndrome of downward accumulation of damp-heat; 3. The ages of 25 to 49 years old; 4. Patients gave informed consent and voluntarily signed informed consent form; 5. Premenopausal and Non-lactating women; 6. No pregnancy plan for nearly 1 year.

排除标准:

①外阴、阴道宫颈高级别病变、宫颈腺上皮病变者。 ②生殖道恶性肿瘤者。 ③合并有严重心、肝、肾功能不良者及精神病患者。 ④过敏体质者,对治疗组所涉及的药物或成分过敏者。 ⑤合并内外科疾病,无法阴道上药及随访者。 ⑥月经不规律,阴道不规则出血,无法阴道上药者。 ⑦2 周内使用其他药物治疗者及参加其他药物临床试验者。

Exclusion criteria:

1. Patients with high-grade epithelial lesions of the lower genital tract; 2. Patients with high-grade vulvar, vaginal, and cervical epithelial lesions, or cervical glandular epithelial lesions; 3. Patients of Malignant tumor of reproductive tract; 4. Patients with cardiachepatic and renal dysfunction,or psychopaths; 5. Patients of allergic constitution Allergic to the drugs or ingredients involved in the treatment group; 6. Combined with internal and surgical diseases, Unable to administer vaginal medication and follow-up; 7. Irregular menstruation, irregular vaginal bleeding, Unable to administer vaginal medication; 8. Patients treated with other drugs within 2 weeks and participants in clinical trials of other drugs.

研究实施时间:

Study execute time:

From 2020-06-01

To      2022-06-30

征募观察对象时间:

Recruiting time:

From 2021-01-01

To      2022-01-01

干预措施:

Interventions:

组别:

治疗组

样本量:

38

Group:

Treatment Group

Sample size:

干预措施:

子门散

干预措施代码:

Intervention:

zimen powder

Intervention code:

组别:

对照组

样本量:

38

Group:

Control Group

Sample size:

干预措施:

干扰素

干预措施代码:

Intervention:

interferon

Intervention code:

样本总量 Total sample size : 76

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

中国中医科学院西苑医院

单位级别:

三级甲等

Institution/hospital:

Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences

Level of the institution:

Tertriary A

测量指标:

Outcomes:

指标中文名:

高危型人乳头瘤病毒

指标类型:

主要指标

Outcome:

HR-HPV

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

调节性T细胞

指标类型:

主要指标

Outcome:

Treg

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

阴道微生态

指标类型:

次要指标

Outcome:

Vaginal microecology

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

宫颈脱落细胞

组织:

Sample Name:

Cervical exfoliated cells

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

宫颈组织

组织:

Sample Name:

Cervical tissue

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

阴道分泌物

组织:

Sample Name:

Vaginal discharge

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 25
Min age years
最大 49
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

原始病例报告表 请阅读网页注册指南中关于 原始数据共享 的内容。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

case report form

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究采用电子数据采集与质疑管理,电子病例报告表(eCRf)中采集的数据应与原始病历、实验室检查报告等原始文件一致

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collected in ECRF should be consisitent with the original medical records,laboratory examination reports and other original documents.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above